2 months Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Bank of America MarketBeat
Bank of America upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $4.20 to $10.00 in a research report on Wednesday.
Bank of America (BAC) · Nasdaq 100 · Pharmaceuticals · Science
X